Qualips Corporation
Basic information
- Head office
- 8F Nakanoshima Qross, 4-3 Nakanoshima, Kita-ku, Osaka, Osaka Prefecture, Japan
- Chief executive
- Takayuki Kusanagi
- Capital
- 1,667,000,000 JPY (16 100 millionJPY)
- Employees (non-consolidated)
- 56 people
- Employees (consolidated)
- 51 people
- Start date
- 2017-03-21
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Cuorips Inc. | ||||||||
|
|
||||||||
| スタンフォード大学 | ||||||||
|
|
||||||||
| 新潟大学大学院医歯学総合研究科 | ||||||||
|
|
||||||||
| 株式会社セルキューブ | ||||||||
|
|
||||||||
| 順天堂大学医学部附属順天堂医院 |
Network
History
The established CellCube Inc. founded Cuore Inc. in Nishi Ward, Yokohama City, Kanagawa Prefecture, to commercialize human iPS cell-derived cardiac muscle cell sheets![]()
Succeeded in business transfer from Cellcube Corporation and inherited the joint research course "Advanced Regenerative Medicine Joint Research Course" in industry-academia collaboration with Osaka University![]()
Received business transfer of human iPS cell-derived cardiac muscle cell sheets from CellCube Inc., and succeeded to the joint research course "Advanced Regenerative Medicine Joint Research Course" with Osaka University (ended at the end of September 2025)![]()
Concluded a joint research agreement with Stanford University Heart and Thoracic Surgery in the United States![]()
Applied for clinical research plan on ischemic heart disease using human iPS cell-derived cardiac muscle cell sheets at Osaka University![]()
Conducted third-party allotment of shares to Daiichi Sankyo Co., Ltd., Kyoto University Innovation Capital Co., Ltd., and others![]()
Osaka University submitted clinical trial notification for physician-led clinical trial on ischemic heart disease using human iPS cell-derived cardiac muscle cell sheets: supporting the physician-led clinical trial (independent administrative agency Pharmaceuticals and Medical Devices Agency (PMDA))![]()
Started construction of a commercial cell culture processing facility (commonly known as "CLiC-1") with a research facility in Minoo City, Osaka Prefecture![]()
Conducted third-party allotment of shares to Daiseki Pharmaceutical Co., Ltd., Kyoto University Innovation Capital Co., Ltd., Terumo Corporation, Daidan Corporation, Stem Cell Research Institute, Asahi Intecc Co., Ltd. (headquartered in Seto, Aichi Prefecture), and others![]()
JIC Venture Growth Investments Co., Ltd. operated JIC Venture Growth Fund No. 1 Investment Limited Partnership, JAFCO Group Co., Ltd. managed JAFCO SV6 Investment Limited Partnership, JAFCO SV6-S Investment Limited Partnership, Kyoto Venture NCC No. 2 Investment Limited Partnership managed by Japan Venture Capital Co., Ltd., Osaka Venture NCC No. 1 Investment Limited Partnership, Fuji Film Co., Ltd., and CellSource Co., Ltd.: conducted third-party allotment of shares to other investors![]()
Fujio Yoshioka, Specially Appointed Professor (Department of Health Sciences, Graduate School of Medicine, Osaka University, Future Medical Science Course), was appointed as CTO (Chief Technology Officer)![]()
Commercial cell culture processing facility (commonly known as "CLiC-1") has obtained "Specific Cell Processing Manufacturing License" (Facility Number: FA5210001)![]()
Agreed to a contract with VC Cell Therapy Inc. regarding clinical trial regenerative medicine products manufacturing and quality control![]()
Concluded a joint research agreement with Asahi Intecc Inc. for the development of new regenerative medicine treatment technologies![]()
The doctor-led clinical trial (Cohort B) has started, and transplantation surgery was performed at Juntendo University School of Medicine Juntendo Hospital (first case transplantation)![]()
Decided to move into Silicon Valley business base (established by the Ministry of Economy, Trade and Industry)![]()
News
First Heart transplant press conference covered by media
The first transplant of the regenerative medicine product 'Heart' was performed, and the surgeon and patient held a press conference. The conference was reported by multiple media outlets including NHK, Sankei, Kyodo, Yomiuri TV, Yomiuri Shimbun, Asahi Shimbun, and Nikkei. The patient reported good postoperative progress and was able to take deep breaths.
ReHeart Second Transplant Press Conference Reported
The press conference regarding the second transplant of the regenerative medicine product "ReHeart" was covered by the media. NHK reported the first iPS cardiomyocyte sheet transplant surgery in Kyushu after insurance coverage, and the Yomiuri Shimbun introduced the surgery using iPS cells at Kyushu University Hospital.
First Transplant of Cuorips’ Regenerative Medicine Product Rehert Covered by Media
Cuorips Co., Ltd. performed the first transplant of Rehert, a regenerative medicine product, and the procedure was covered by multiple media outlets. Surgery using an iPS cell-derived cardiac muscle sheet was performed at a hospital in Osaka and has drawn attention as the world’s first practical application. Comments from the Chief Medical Science Officer were also published.
Sankei News Publishes Interview with Chief Medical Science Officer on 20 Years of iPS Cells
Sankei News published an interview on August 17, 2026, marking 20 years of iPS cell research. Chief Medical Science Officer Sawada discussed progress in regenerative medicine and new treatment options for severe heart failure.
Public records
National Tax Agency basic information7020001120540
- Trade name
- クオリプス株式会社
- Trade name (kana)
- クオリプス
- Name in English
- Corporation type
- 301
- Address
- 〒103-0023 東京都中央区日本橋本町3丁目11番5号日本橋ライフサイエンスビルディング2、507
- Postal code
- 1030023
- Prefecture code
- 13
- City code
- 102
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2017-03-27
- Update date
- 2018-07-09
- Change date
- 2018-07-02
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 2306342
METI gBizINFO7020001120540
- Corporate number
- 7020001120540
- Trade name
- クオリプス株式会社
- Trade name (kana)
- クオリプス
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 大阪府大阪市北区中之島4丁目3番51号NakanoshimaQross8F、O-Nexus内
- Postal code
- 5300005
- Prefecture
- 大阪府
- Prefecture code
- 27
- City or district
- 大阪市北区
- City code
- 127
- Street address
- 中之島4丁目3番51号NakanoshimaQross8F、O-Nexus内
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 0
- Status
- Representative
- 代表取締役社長 草薙 尊之
- Capital
- 1769678000
- Employees
- 51
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2026-09-07
- Key information
- 7020001120540